Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Vanda Pharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding Vanda Pharmaceuticals Inc.’s stock price such as:

• Vanda Pharmaceuticals Inc.’s current stock price and volume
• Why Vanda Pharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for VNDA from analysts
• VNDA’s stock price momentum as measured by its relative strength

About Vanda Pharmaceuticals Inc. (VNDA)

Before we jump into Vanda Pharmaceuticals Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company’s products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Want to learn more about Vanda Pharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Vanda Pharmaceuticals Inc..

Vanda Pharmaceuticals Inc.’s Stock Price as of Market Close

As of April 16, 2026, 3:33 PM, CST, Vanda Pharmaceuticals Inc.’s stock price was $7.135.

Vanda Pharmaceuticals Inc. is down 1.86% from its previous closing price of $7.270.

During the last market session, Vanda Pharmaceuticals Inc.’s stock traded between $7.020 and $7.280. Currently, there are approximately 59.10 million shares outstanding for Vanda Pharmaceuticals Inc..

Vanda Pharmaceuticals Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Vanda Pharmaceuticals Inc. Stock Price History

Vanda Pharmaceuticals Inc.’s (VNDA) price is currently up 3.26% so far this month.

During the month of April, Vanda Pharmaceuticals Inc.’s stock price has reached a high of $7.790 and a low of $6.760.

Over the last year, Vanda Pharmaceuticals Inc. has hit prices as high as $9.940 and as low as $3.809. Year to date, Vanda Pharmaceuticals Inc.’s stock is down 19.1%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Vanda Pharmaceuticals Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 15, 2026, there were analysts who downgraded Vanda Pharmaceuticals Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Vanda Pharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Vanda Pharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Vanda Pharmaceuticals Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Vanda Pharmaceuticals Inc. (VNDA) by visiting AAII Stock Evaluator.

Relative Price Strength of Vanda Pharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 15, 2026, Vanda Pharmaceuticals Inc. has a weighted four-quarter relative price strength of 5.05%, which translates to a Momentum Score of 68 and is considered to be Strong.

Want to learn more about how Vanda Pharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Vanda Pharmaceuticals Inc. Stock Price: Bottom Line

As of April 16, 2026, Vanda Pharmaceuticals Inc.’s stock price is $7.135, which is down 1.86% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Vanda Pharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.